Fosamax, or alendronate, is a prescription medication used to treat and prevent osteoporosis. It’s one of the most commonly prescribed drugs for this condition, which affects millions of people around the world. But with any medication comes questions about proper dosing, safety and potential interactions with other drugs and supplements. To ensure you make the most out of Fosamax’s benefits without running into any risks, here’s everything you need to know about this drug—from dose to interactions and safety.
Fosamax (alendronate) is a prescription medication used to treat and prevent osteoporosis in women after menopause. It belongs to a class of drugs called bisphosphonates. Fosamax works by slowing bone loss and increasing bone density (thickness), which may prevent fractures.
The U.S. Food and Drug Administration (FDA) approved Fosamax in 1995. Merck & Co., Inc., manufactures it.
The recommended dose of Fosamax is 70 mg once weekly. It can be taken with or without food. If you take it with food, you should take it on the same day each week.
If you miss a dose of Fosamax, you should take it as soon as possible. If it is more than 12 hours late, you should skip the missed dose and take your next dose on the regular schedule. Do not take two doses of Fosamax at the same time.
Fosamax may interact with other medications. During pregnancy, Fosamax should be used only when prescribed. This medication passes into breast milk and could have undesirable effects on a nursing infant.
There are a few things to be aware of when taking Fosamax, as it can interact with other medications and medical conditions. For example, people with kidney disease should not take Fosamax, as it can further damage the kidneys. People with low blood calcium levels may also need to avoid Fosamax, as it can cause further decreases in calcium levels.
Additionally, Fosamax can interact with other medications, such as bisphosphonates, thyroid hormone, and warfarin.
Overall, Fosamax is a safe medication when used as directed. However, like all medications, there are potential side effects associated with taking Fosamax. The most common side effects include stomach upset and diarrhea. More serious side effects are rare but can include problems with the esophagus and bone pain.
Fosamax (alendronate) is a prescription medication used to treat osteoporosis in women after menopause. It belongs to a class of drugs called bisphosphonates.
Common side effects of Fosamax include
stomach upset,
heartburn,
nausea, and
diarrhea.
More serious side effects include:
esophageal ulcers,
ocular problems, and
Musculoskeletal pain.
Fosamax is a medication used in the treatment of osteoporosis. It can be a very effective way to prevent and treat bone loss caused by this condition. However, it is important to understand how Fosamax works, potential side effects and drug interactions before starting use. By understanding all of these factors, you will be able to make an informed decision about whether or not Fosamax is suitable for your needs.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Charles III, King of Kings, is Cancerous.
2.
Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.
3.
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival
4.
Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.
5.
WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research
1.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
2.
Ultimate Guide to Oncology Services in the USA
3.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
4.
Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools
5.
Introducing the Corrected Calcium Calculator: A Revolutionary Tool in Medical Assessment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Oropharyngeal Cancer in Relation to HPV Status
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
3.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation